News Releases

Month Year

Email Alerts

May 7, 2015

Insmed Reports First Quarter 2015 Financial Results
Apr 6, 2015

Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
Mar 31, 2015

Insmed Announces Pricing of Public Offering of Common Stock
Mar 30, 2015

Insmed Announces Proposed Public Offering of Common Stock
Mar 27, 2015

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 23, 2015

Insmed Appoints Dr. Eugene Sullivan as Chief Medical and Scientific Officer

20 Year Industry Veteran Brings Industry, Clinical and Regulatory Experience in Pulmonary and Orphan Diseases
Feb 27, 2015

Insmed Reports 2014 Fourth Quarter and Full Year Financial Results

Marketing Authorization Application for ARIKAYCETM Validated by the European Medicines Agency
Feb 24, 2015

Insmed to Participate at Cowen & Company's 35th Annual Health Care Conference
Jan 28, 2015

Insmed to Participate at February Investment Conferences
Jan 13, 2015

Insmed Incorporated Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 6, 2015

Insmed to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Dec 15, 2014

Insmed Provides End of Year Regulatory and Clinical Update
Dec 15, 2014

Insmed Appoints Myrtle Potter to its Board of Directors

Pharmaceutical executive brings 30 years of commercial and operations leadership
Nov 26, 2014

Insmed to Participate at December Investment Conferences
Nov 6, 2014

Insmed Reports Third Quarter 2014 Financial Results

Conference Call Begins Today at 8:30 a.m. Eastern Time
Sep 24, 2014

Insmed to Participate in Leerink Partners' Rare Disease Roundtable
Sep 3, 2014

Insmed Announces Multiple Clinical and Scientific Presentations at European Respiratory Society's International Congress 2014
Aug 18, 2014

Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
Aug 12, 2014

Insmed Announces Pricing of Public Offering of Common Stock
Aug 6, 2014

Insmed Reports Second Quarter 2014 Financial Results
Aug 4, 2014

Insmed Provides Regulatory Update for ARIKAYCE

Filing Marketing Authorization Application with European Medicines Agency for NTM Lung Disease and CF Indications
Jun 20, 2014

Insmed to Present at the JMP Securities Healthcare Conference
May 29, 2014

Insmed Appoints David R. Brennan to Its Board of Directors
May 20, 2014

Insmed Announces Positive Open Label Data from Phase 2 Clinical Trial of ARIKAYCE for Treatment Resistant Nontuberculous Mycobacterial Lung Infections

Poster Presentation at the American Thoracic Society Annual Meeting 2014
May 13, 2014

Insmed Announces Data Presentations for ARIKAYCE in Two Orphan Lung Diseases at the American Thoracic Society Meeting
May 12, 2014

Insmed to Participate in the Bank of America Merrill Lynch 2014 Health Care Conference
May 8, 2014

Insmed Reports First Quarter 2014 Financial Results
Apr 7, 2014

Insmed to Participate in the 13th Annual Needham & Co. Healthcare Conference
Apr 2, 2014

Insmed Announces Leadership Team Transitions and Appointments to Expand Support for Growth Opportunities
Mar 26, 2014

Insmed Announces Results from Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacterial Lung Infections

Conference Call with Insmed Management and Clinical Trial Investigators Will be Held Today at 8:00 a.m. Eastern Time
Mar 25, 2014

Insmed to Announce Results From U.S. Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacteria Lung Infections
Mar 6, 2014

Insmed Reports 2013 Fourth Quarter and Full Year Financial Results
Feb 19, 2014

Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients

Initial 12-Month Data Demonstrate Long-Term Safety and Durability of Effect
Feb 10, 2014

ARIKACE to Receive Orphan Medicinal Product Designation in the European Union to Treat Lung Infections Caused by Nontuberculous Mycobacteria
Feb 4, 2014

Insmed to Present at the Leerink Swann Global Healthcare Conference
Feb 4, 2014

Insmed to Present at the Leerink Swann Global Healthcare Conference
Nov 5, 2013

Insmed Reports Third Quarter 2013 Financial Results
Nov 1, 2013

Insmed Appoints David W.J. McGirr to Its Board of Directors
Oct 23, 2013

Insmed to Host Third Quarter 2013 Financial Results Conference Call on Tuesday, November 5, 2013
Oct 15, 2013

Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada
Sep 15, 2013

Insmed to Present at Leerink Swann Rare Disease Roundtable
Sep 11, 2013

Insmed Fortifies Global Patent Portfolio
Sep 4, 2013

Insmed to Participate in the Stifel Healthcare Conference 2013
Aug 7, 2013

Insmed to Participate in August Investor Conferences
Aug 6, 2013

Insmed Reports Second Quarter Financial Results
Jul 31, 2013

Insmed to Host Second Quarter 2013 Financial Results Conference Call on Tuesday, August 6, 2013
Jul 29, 2013

Insmed Appoints Christine Pellizzari as General Counsel and Corporate Secretary
Jul 22, 2013

Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
Jul 17, 2013

Insmed Announces Pricing of Public Offering of Common Stock
Jul 15, 2013

Insmed Announces Proposed Public Offering of Common Stock

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation

Download

Our Global Company

Current Clinical Trials

Our Research Team

Our Global Company

Current Clinical Trials

Our Research Team

Footer